Tissue-Specific Delivery of Oligonucleotides.

From the initial discovery of short-interfering RNA (siRNA) and antisense oligonucleotides for specific gene knockdown at the posttranscriptional level to the current CRISPR-Cas9 system offering gene editing at the genomic level, oligonucleotides, in addition to their biological functions in storing and conveying genetic information, provide the most prominent solutions to targeted gene therapies. Nonetheless, looking into the future of curing cancer and acute diseases, researchers are only cautiously optimistic as the cellular delivery of these polyanionic biomacromolecules is still the biggest hurdle for their therapeutic realization. To overcome the delivery obstacle, oligonucleotides have been encapsulated within or conjugated with delivery vehicles for enhanced membrane penetration, improved payload, and tissue-specific delivery. Such delivery systems include but not limited to virus-based vehicles, gold-nanoparticle vehicles, formulated liposomes, and synthetic polymers. In this chapter, delivery challenges imposed by biological barriers are briefly discussed; followed by recent advances in tissue-specific oligonucleotide delivery utilizing both viral and nonviral delivery vectors, discussing their advantages, and how judicious design and formulation could improve and expand their potential as delivery vehicles.

[1]  Jinwoo Cheon,et al.  All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery. , 2009, Angewandte Chemie.

[2]  Dale L. Greiner,et al.  T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized Mice , 2008, Cell.

[3]  You Han Bae,et al.  pH-responsive sulfonamide/PEI system for tumor specific gene delivery: an in vitro study. , 2006, Biomacromolecules.

[4]  Hua Yu,et al.  TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. , 2013, Blood.

[5]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[6]  Xiaoyang Xu,et al.  Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. , 2014, Advanced drug delivery reviews.

[7]  W. Fan,et al.  Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy , 2011, International journal of nanomedicine.

[8]  G. P. Smith,et al.  Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. , 1985, Science.

[9]  Abhay Pandit,et al.  Polymer gene delivery: overcoming the obstacles. , 2013, Drug discovery today.

[10]  Mengsu Yang,et al.  Efficient RNA drug delivery using red blood cell extracellular vesicles , 2018, Nature Communications.

[11]  R. Crouch,et al.  Ribonuclease H: the enzymes in eukaryotes , 2009, The FEBS journal.

[12]  S. Akira,et al.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors , 2010, Nature Immunology.

[13]  Z. Qian,et al.  Transferrin/transferrin receptor-mediated drug delivery. , 2002, Medicinal research reviews.

[14]  Robert J Gillies,et al.  Acidity generated by the tumor microenvironment drives local invasion. , 2013, Cancer research.

[15]  Xiaoyuan Chen,et al.  Aptamer-Drug Conjugates. , 2015, Bioconjugate chemistry.

[16]  Eric T. Wang,et al.  Barcoded nanoparticles for high throughput in vivo discovery of targeted therapeutics , 2017, Proceedings of the National Academy of Sciences.

[17]  Leaf Huang,et al.  Gene therapy progress and prospects: non-viral gene therapy by systemic delivery , 2006, Gene Therapy.

[18]  P. Morcos.  Achieving targeted and quantifiable alteration of mRNA splicing with Morpholino oligos. , 2007, Biochemical and biophysical research communications.

[19]  Kaihong Zhou,et al.  Receptor-Mediated Delivery of CRISPR-Cas9 Endonuclease for Cell-Type-Specific Gene Editing. , 2018, Journal of the American Chemical Society.

[20]  C. Esposito,et al.  Aptamer Cell-Based Selection: Overview and Advances , 2017, Biomedicines.

[21]  Rongqin Huang,et al.  A leptin derived 30-amino-acid peptide modified pegylated poly-L-lysine dendrigraft for brain targeted gene delivery. , 2010, Biomaterials.

[22]  Robert Langer,et al.  A combinatorial polymer library approach yields insight into nonviral gene delivery. , 2008, Accounts of chemical research.

[23]  A. Levitzki,et al.  EGF Receptor-Targeted Synthetic Double-Stranded RNA Eliminates Glioblastoma, Breast Cancer, and Adenocarcinoma Tumors in Mice , 2005, PLoS medicine.

[24]  R. R. Rice,et al.  Simple, robust strategies for generating DNA-directed RNA interference constructs. , 2005, Methods in enzymology.

[25]  O. Hobert.  Gene Regulation by Transcription Factors and MicroRNAs , 2008, Science.

[26]  D. Shangguan,et al.  Aptamers evolved from live cells as effective molecular probes for cancer study , 2006, Proceedings of the National Academy of Sciences.

[27]  Gaurav Sahay,et al.  Challenges in carrier-mediated intracellular delivery: moving beyond endosomal barriers. , 2016, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[28]  L. Naldini.  Ex vivo gene transfer and correction for cell-based therapies , 2011, Nature Reviews Genetics.

[29]  P. Guo,et al.  Construction of folate-conjugated pRNA of bacteriophage phi29 DNA packaging motor for delivery of chimeric siRNA to nasopharyngeal carcinoma cells , 2006, Gene Therapy.

[30]  K. G. Rajeev,et al.  Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates , 2017, Nucleic acids research.

[31]  Helmuth Möhwald,et al.  RGD peptide-modified dendrimer-entrapped gold nanoparticles enable highly efficient and specific gene delivery to stem cells. , 2015, ACS applied materials & interfaces.

[32]  T. Cotter,et al.  Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy. , 2017, Molecular pharmaceutics.

[33]  J. Novak,et al.  Glycosylation Patterns of HIV-1 gp120 Depend on the Type of Expressing Cells and Affect Antibody Recognition , 2010, The Journal of Biological Chemistry.

[34]  Eunjung Kim,et al.  Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. , 2010, Biomaterials.

[35]  P. Low,et al.  Ligand‐Targeted Delivery of Small Interfering RNAs to Malignant Cells and Tissues , 2009, Annals of the New York Academy of Sciences.

[36]  David Cunliffe,et al.  Thermo and pH responsive polymers as gene delivery vectors: effect of polymer architecture on DNA complexation in vitro. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[37]  T. Niidome,et al.  Folate-PEG-appended dendrimer conjugate with α-cyclodextrin as a novel cancer cell-selective siRNA delivery carrier. , 2012, Molecular pharmaceutics.

[38]  Chin-Tarng Lin,et al.  Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery , 2008, Molecular Cancer Therapeutics.

[39]  Yong Wang,et al.  Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras , 2006, Nature Biotechnology.

[40]  W. Pardridge,et al.  Drug and gene targeting to the brain with molecular trojan horses , 2002, Nature Reviews Drug Discovery.

[41]  L. Pereira de Almeida,et al.  Tumor-targeted Chlorotoxin-coupled Nanoparticles for Nucleic Acid Delivery to Glioblastoma Cells: A Promising System for Glioblastoma Treatment , 2013, Molecular therapy. Nucleic acids.

[42]  P. Low,et al.  Principles in the design of ligand-targeted cancer therapeutics and imaging agents , 2015, Nature Reviews Drug Discovery.

[43]  J. Marks,et al.  Targeted gene delivery to mammalian cells by filamentous bacteriophage. , 1999, Journal of molecular biology.

[44]  Young Jik Kwon,et al.  Efficient and targeted delivery of siRNA in vivo , 2010, The FEBS journal.

[45]  M. Cilli,et al.  Neuroblastoma-targeted nanoparticles entrapping siRNA specifically knockdown ALK. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[46]  T. Woolf.  To cleave or not to cleave: ribozymes and antisense. , 1995, Antisense research and development.

[47]  Daniel G. Anderson,et al.  Molecularly Self-Assembled Nucleic Acid Nanoparticles for Targeted In Vivo siRNA Delivery , 2012, Nature nanotechnology.

[48]  F. Huang,et al.  Rational design of targeted cancer therapeutics through the multiconjugation of folate and cleavable siRNA to RAFT-synthesized (HPMA-s-APMA) copolymers. , 2010, Biomacromolecules.

[49]  Hua Lu,et al.  Site-specific antibody-polymer conjugates for siRNA delivery. , 2013, Journal of the American Chemical Society.

[50]  K. Lee,et al.  T cell-specific siRNA delivery using antibody-conjugated chitosan nanoparticles. , 2012, Bioconjugate chemistry.

[51]  Mark A. Kay,et al.  Progress and problems with the use of viral vectors for gene therapy , 2003, Nature Reviews Genetics.

[52]  M. Bawendi,et al.  Renal clearance of quantum dots , 2007, Nature Biotechnology.

[53]  P. Herdewijn,et al.  Antisense PNA tridecamers targeted to the coding region of Ha-ras mRNA arrest polypeptide chain elongation. , 1999, Journal of molecular biology.

[54]  T. Reineke,et al.  New poly(d-glucaramidoamine)s induce DNA nanoparticle formation and efficient gene delivery into mammalian cells. , 2004, Journal of the American Chemical Society.

[55]  Rakesh K. Jain,et al.  Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.

[56]  S. Milstein,et al.  Hepatocyte‐Specific Delivery of siRNAs Conjugated to Novel Non‐nucleosidic Trivalent N‐Acetylgalactosamine Elicits Robust Gene Silencing in Vivo , 2015, Chembiochem : a European journal of chemical biology.

[57]  Hideyoshi Harashima,et al.  A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. , 2011, Advanced drug delivery reviews.

[58]  Anne L. van de Ven,et al.  Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. , 2013, Nature nanotechnology.

[59]  M. Fabbri,et al.  MicroRNAs and other non-coding RNAs as targets for anticancer drug development , 2013, Nature Reviews Drug Discovery.

[60]  Philip M. Kelly,et al.  Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. , 2013, Nature nanotechnology.

[61]  Kenneth I. Berns,et al.  Gene Therapy Using Adeno-Associated Virus Vectors , 2008, Clinical Microbiology Reviews.

[62]  Daniel G. Anderson,et al.  Non-viral vectors for gene-based therapy , 2014, Nature Reviews Genetics.

[63]  D W Pack,et al.  Polymer-based gene delivery with low cytotoxicity by a unique balance of side-chain termini. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[64]  M. Ogris,et al.  Induction of apoptosis in murine neuroblastoma by systemic delivery of transferrin-shielded siRNA polyplexes for downregulation of Ran. , 2008, Oligonucleotides.

[65]  Nicholas A Peppas,et al.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.

[66]  Véronique Préat,et al.  To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[67]  F. Huang,et al.  Facile synthesis of multivalent folate-block copolymer conjugates via aqueous RAFT polymerization: targeted delivery of siRNA and subsequent gene suppression. , 2009, Biomacromolecules.

[68]  M. Behlke,et al.  Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides , 2015, Nucleic acids research.

[69]  P. Ponka.  Iron and cell proliferation: another piece of the puzzle , 2004 .

[70]  Luigi Naldini,et al.  Gene therapy returns to centre stage , 2015, Nature.

[71]  Dipali G. Sashital,et al.  Structural insights into RNA interference. , 2010, Current opinion in structural biology.

[72]  Rongqin Huang,et al.  Targeted delivery of chlorotoxin-modified DNA-loaded nanoparticles to glioma via intravenous administration. , 2011, Biomaterials.

[73]  M. Hashida,et al.  Targeted delivery of plasmid DNA to hepatocytes in vivo: optimization of the pharmacokinetics of plasmid DNA/galactosylated poly(L-lysine) complexes by controlling their physicochemical properties. , 1998, The Journal of pharmacology and experimental therapeutics.

[74]  B. Liu,et al.  Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[75]  Sanjiv Sonkaria,et al.  Targeting C-type lectin receptors with multivalent carbohydrate ligands. , 2013, Advanced drug delivery reviews.

[76]  In Su Lee,et al.  Surface functionalized hollow manganese oxide nanoparticles for cancer targeted siRNA delivery and magnetic resonance imaging. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[77]  O. Uhlenbeck,et al.  RNA aptamers as pathway-specific MAP kinase inhibitors. , 2000, Chemistry & biology.

[78]  S. Rosenberg,et al.  Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.

[79]  N. Fedoroff,et al.  The Arabidopsis double-stranded RNA-binding protein HYL1 plays a role in microRNA-mediated gene regulation. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[80]  Xiaoli Wei,et al.  A D-peptide ligand of nicotine acetylcholine receptors for brain-targeted drug delivery. , 2015, Angewandte Chemie.

[81]  M. Lindow,et al.  RNase H sequence preferences influence antisense oligonucleotide efficiency , 2017, Nucleic acids research.

[82]  R. Hoogenboom.  Temperature-responsive polymers: properties, synthesis and applications , 2014 .

[83]  T. Minko,et al.  Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[84]  Matthias John,et al.  RNAi-mediated gene silencing in non-human primates , 2006, Nature.

[85]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[86]  E. Ohtsuka,et al.  Sequence‐dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H , 1987, Nucleic acids symposium series.

[87]  S. Nishimura,et al.  Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[88]  D. Schaffert,et al.  Poly(I:C)-Mediated Tumor Growth Suppression in EGF-Receptor Overexpressing Tumors Using EGF-Polyethylene Glycol-Linear Polyethylenimine as Carrier , 2011, Pharmaceutical Research.

[89]  K. G. Rajeev,et al.  Multivalent cyclic RGD conjugates for targeted delivery of small interfering RNA. , 2011, Bioconjugate chemistry.

[90]  Robert Langer,et al.  Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. , 2017, Nano letters.

[91]  Chen Jiang,et al.  Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles. , 2009, Biomaterials.

[92]  R. Bambara,et al.  Junction ribonuclease: an activity in Okazaki fragment processing. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[93]  Zhibo Li,et al.  Biodegradable stimuli-responsive polypeptide materials prepared by ring opening polymerization. , 2015, Chemical Society reviews.

[94]  C. Culmsee,et al.  siRNA delivery by a transferrin‐associated lipid‐based vector: a non‐viral strategy to mediate gene silencing , 2007, The journal of gene medicine.

[95]  Mauro Ferrari,et al.  Principles of nanoparticle design for overcoming biological barriers to drug delivery , 2015, Nature Biotechnology.

[96]  Daniel G. Anderson,et al.  Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.

[97]  Anna Moore,et al.  In vivo imaging of siRNA delivery and silencing in tumors , 2007, Nature Medicine.

[98]  Jun Wang,et al.  Smart Superstructures with Ultrahigh pH-Sensitivity for Targeting Acidic Tumor Microenvironment: Instantaneous Size Switching and Improved Tumor Penetration. , 2016, ACS nano.

[99]  J. Bisi,et al.  An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers. , 1995, Nucleic acids research.

[100]  J. Walder,et al.  Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[101]  T. Tuschl,et al.  Mechanisms of gene silencing by double-stranded RNA , 2004, Nature.

[102]  Julie N. L. Albert,et al.  Stimuli-responsive copolymer solution and surface assemblies for biomedical applications. , 2013, Chemical Society reviews.

[103]  Mark E. Davis,et al.  Imidazole groups on a linear, cyclodextrin-containing polycation produce enhanced gene delivery via multiple processes. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[104]  M. Carmell,et al.  Posttranscriptional Gene Silencing in Plants , 2006 .

[105]  R. Haag,et al.  Defined pH-sensitive nanogels as gene delivery platform for siRNA mediated in vitro gene silencing. , 2017, Biomaterials science.

[106]  Meredith A Mintzer,et al.  Nonviral vectors for gene delivery. , 2009, Chemical reviews.

[107]  Jun Fang,et al.  The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. , 2011, Advanced drug delivery reviews.

[108]  B. Dijkmans,et al.  Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients. , 2009, Arthritis and rheumatism.

[109]  Samir Mitragotri,et al.  Platelet-like Nanoparticles: Mimicking Shape, Flexibility, and Surface Biology of Platelets To Target Vascular Injuries , 2014, ACS nano.

[110]  John J Rossi,et al.  Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[111]  S. Harper,et al.  Viral delivery of recombinant short hairpin RNAs. , 2005, Methods in enzymology.

[112]  K. Morris,et al.  Receptor-targeted aptamer-siRNA conjugate-directed transcriptional regulation of HIV-1 , 2018, Theranostics.

[113]  R. Schiffelers,et al.  Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. , 2004, Nucleic acids research.

[114]  M. Furusawa,et al.  Injection of foreign substances into single cells by cell fusion , 1974, Nature.

[115]  Laura M Ensign,et al.  PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. , 2016, Advanced drug delivery reviews.

[116]  I. Hirao,et al.  DNA aptamer generation by ExSELEX using genetic alphabet expansion with a mini-hairpin DNA stabilization method. , 2017, Biochimie.

[117]  Luigi Naldini,et al.  Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics , 2001, Nature Medicine.

[118]  Gert Storm,et al.  Endosomal escape pathways for delivery of biologicals. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[119]  Xinguo Jiang,et al.  The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. , 2012, Biomaterials.

[120]  A. Takayanagi,et al.  A novel gene delivery system using EGF receptor‐mediated endocytosis , 1994, FEBS letters.

[121]  Xiaoling Zhang,et al.  Low molecular weight chitosan conjugated with folate for siRNA delivery in vitro: optimization studies , 2012, International journal of nanomedicine.

[122]  K. Jensen,et al.  In vitro and ex vivo strategies for intracellular delivery , 2016, Nature.

[123]  I. Zuhorn,et al.  Smuggling Drugs into the Brain: An Overview of Ligands Targeting Transcytosis for Drug Delivery across the Blood–Brain Barrier , 2014, Pharmaceutics.

[124]  A.V. Lakhin,et al.  Aptamers: Problems, Solutions and Prospects , 2013, Acta naturae.

[125]  J. M. Harris,et al.  Effect of pegylation on pharmaceuticals , 2003, Nature Reviews Drug Discovery.

[126]  D. Weissman,et al.  Exogenous siRNA Mediates Sequence-Independent Gene Suppression by Signaling through Toll-Like Receptor 3 , 2004, Cells Tissues Organs.

[127]  J. S. Park,et al.  Receptor-mediated gene delivery into human mesenchymal stem cells using hyaluronic acid-shielded polyethylenimine/pDNA nanogels. , 2016, Carbohydrate polymers.

[128]  Ming Yao,et al.  Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[129]  M. Kraus,et al.  Implications of acidic tumor microenvironment for neoplastic growth and cancer treatment: a computer analysis. , 1996, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[130]  Forrest M Kievit,et al.  Chlorotoxin bound magnetic nanovector tailored for cancer cell targeting, imaging, and siRNA delivery. , 2010, Biomaterials.

[131]  Soonhag Kim,et al.  Molecular imaging of a cancer-targeting theragnostics probe using a nucleolin aptamer- and microRNA-221 molecular beacon-conjugated nanoparticle. , 2012, Biomaterials.

[132]  G. Zhai,et al.  Chondroitin sulfate-based nanocarriers for drug/gene delivery. , 2015, Carbohydrate polymers.

[133]  Kai-Wen Huang,et al.  Targeted Delivery of C/EBPα -saRNA by Pancreatic Ductal Adenocarcinoma-specific RNA Aptamers Inhibits Tumor Growth In Vivo , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[134]  L. Gening,et al.  Isolation and characterization of high affinity aptamers against DNA polymerase iota. , 2012, Nucleic Acid Therapeutics.

[135]  Yuko Nakamura,et al.  Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer? , 2016, Bioconjugate chemistry.

[136]  A. Levitzki,et al.  PSMA-targeted polyinosine/polycytosine vector induces prostate tumor regression and invokes an antitumor immune response in mice , 2017, Proceedings of the National Academy of Sciences.

[137]  J. Mattick,et al.  Structure and function of long noncoding RNAs in epigenetic regulation , 2013, Nature Structural &Molecular Biology.

[138]  S. W. Kim,et al.  Tumor targeting RGD conjugated bio-reducible polymer for VEGF siRNA expressing plasmid delivery. , 2014, Biomaterials.

[139]  William R. Schief,et al.  Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies , 2015, Nature Communications.

[140]  S. Milstein,et al.  siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes. , 2015, ACS chemical biology.

[141]  Samuel A. Mihelic,et al.  Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted siRNA Delivery to HER2+ Breast Cancer , 2015, Advanced functional materials.

[142]  Samir Mitragotri,et al.  Red blood cells: Supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems. , 2016, Advanced drug delivery reviews.

[143]  M. Wood,et al.  Therapeutic targeting of non-coding RNAs. , 2013, Essays in biochemistry.

[144]  R. Langer,et al.  Exploring polyethylenimine‐mediated DNA transfection and the proton sponge hypothesis , 2005, The journal of gene medicine.

[145]  Mansoor Amiji,et al.  Tumor-Targeted Gene Delivery Using Poly(Ethylene Glycol)-Modified Gelatin Nanoparticles: In Vitro and in Vivo Studies , 2005, Pharmaceutical Research.

[146]  K. G. Rajeev,et al.  A Glu-urea-Lys Ligand-conjugated Lipid Nanoparticle/siRNA System Inhibits Androgen Receptor Expression In Vivo , 2016, Molecular therapy. Nucleic acids.

[147]  Amy Chan,et al.  Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. , 2014, Journal of the American Chemical Society.

[148]  A. Krainer,et al.  RNA therapeutics: beyond RNA interference and antisense oligonucleotides , 2012, Nature Reviews Drug Discovery.

[149]  Silvia Catuogno,et al.  Multifunctional aptamer-miRNA conjugates for targeted cancer therapy. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[150]  Lili Wang,et al.  Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[151]  Mark E. Davis,et al.  PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. , 2004, European journal of cell biology.

[152]  Xiaohu Gao,et al.  A ribonucleoprotein octamer for targeted siRNA delivery , 2018, Nature Biomedical Engineering.

[153]  Judy Lieberman,et al.  Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors , 2005, Nature Biotechnology.

[154]  T. Nakamura,et al.  Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. , 1999, Arthritis and rheumatism.

[155]  W. Pardridge.  shRNA and siRNA delivery to the brain. , 2007, Advanced drug delivery reviews.

[156]  John J Rossi,et al.  Approaches for the sequence-specific knockdown of mRNA , 2003, Nature Biotechnology.

[157]  Harald Sontheimer,et al.  Chlorotoxin Inhibits Glioma Cell Invasion via Matrix Metalloproteinase-2* , 2003, The Journal of Biological Chemistry.

[158]  T. Przytycka,et al.  Aptamer-Drug Conjugates of Active Metabolites of Nucleoside Analogs and Cytotoxic Agents Inhibit Pancreatic Tumor Cell Growth , 2016, Molecular therapy. Nucleic acids.

[159]  J Henke,et al.  Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo , 2002, Gene Therapy.

[160]  Zhen Gu,et al.  Anticancer Platelet‐Mimicking Nanovehicles , 2015, Advanced materials.

[161]  Ton N. Schumacher,et al.  Adoptive cellular therapy: A race to the finish line , 2015, Science Translational Medicine.

[162]  C. Cho,et al.  Synergistic effect of poly(ethylenimine) on the transfection efficiency of galactosylated chitosan/DNA complexes. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[163]  R. Kole,et al.  Switching on transgene expression by correcting aberrant splicing using multi‐targeting steric‐blocking oligonucleotides , 2007, The journal of gene medicine.

[164]  R. Simmons,et al.  Transfer of iron from serum iron-binding protein to human reticulocytes. , 1959, The Journal of clinical investigation.

[165]  K. Morris,et al.  Small Interfering RNA-Induced Transcriptional Gene Silencing in Human Cells , 2004, Science.

[166]  Laurence Tetley,et al.  Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNA. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[167]  Mark E. Davis,et al.  New class of polymers for the delivery of macromolecular therapeutics. , 1999 .

[168]  Rongqin Huang,et al.  Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[169]  P. Sharp,et al.  RNAi Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals , 2000, Cell.

[170]  B. Li,et al.  Co-delivery of Doxorubicin and Bmi1 siRNA by Folate Receptor Targeted Liposomes Exhibits Enhanced Anti-Tumor Effects in vitro and in vivo , 2014, Theranostics.

[171]  A Mukherjee,et al.  Nucleic acid aptamers: clinical applications and promising new horizons. , 2011, Current medicinal chemistry.

[172]  E. Wardelmann,et al.  Antibody-Mediated Delivery of Anti–KRAS-siRNA In Vivo Overcomes Therapy Resistance in Colon Cancer , 2015, Clinical Cancer Research.

[173]  E. Zacco,et al.  Tailored Presentation of Carbohydrates on a Coiled Coil-Based Scaffold for Asialoglycoprotein Receptor Targeting. , 2015, ACS chemical biology.

[174]  Peter D. Kwong,et al.  The Mannose-Dependent Epitope for Neutralizing Antibody 2G12 on Human Immunodeficiency Virus Type 1 Glycoprotein gp120 , 2002, Journal of Virology.

[175]  Anton P. McCaffrey,et al.  Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors , 2009, Nature Biotechnology.

[176]  Mark E. Davis,et al.  Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor , 2013, Proceedings of the National Academy of Sciences.

[177]  Michael T. McManus,et al.  Gene silencing in mammals by small interfering RNAs , 2002, Nature Reviews Genetics.

[178]  Daniel G. Anderson,et al.  Supramolecular PEGylation of biopharmaceuticals , 2016, Proceedings of the National Academy of Sciences.

[179]  S. Akira,et al.  Toll-like receptors. , 2003, Annual review of immunology.

[180]  Erkki Ruoslahti,et al.  Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule , 1984, Nature.

[181]  Alan Aderem,et al.  Phagocytosis and the inflammatory response. , 2003, The Journal of infectious diseases.

[182]  Cui Tang,et al.  Dual-targeting and pH/redox-responsive multi-layered nanocomplexes for smart co-delivery of doxorubicin and siRNA. , 2015, Biomaterials.

[183]  M. Gu,et al.  An ultra-sensitive colorimetric detection of tetracyclines using the shortest aptamer with highly enhanced affinity. , 2014, Chemical communications.

[184]  Rongqin Huang,et al.  Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer , 2007 .

[185]  S. Crooke,et al.  RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[186]  G. Coceano,et al.  Glucose is a key driver for GLUT1-mediated nanoparticles internalization in breast cancer cells , 2016, Scientific Reports.

[187]  Dennis E Discher,et al.  Minimal " Self " Peptides That Inhibit Phagocytic Clearance and Enhance Delivery of Nanoparticles References and Notes , 2022 .

[188]  Scott H. Medina,et al.  N-acetylgalactosamine-functionalized dendrimers as hepatic cancer cell-targeted carriers. , 2011, Biomaterials.

[189]  Lin Lin,et al.  pH-Triggered Sheddable Shielding System for Polycationic Gene Carriers , 2016, Polymers.

[190]  B. Shen,et al.  Saccharomyces cerevisiae RNase H(35) Functions in RNA Primer Removal during Lagging-Strand DNA Synthesis, Most Efficiently in Cooperation with Rad27 Nuclease , 1999, Molecular and Cellular Biology.

[191]  Daniel W. Pack,et al.  Design and development of polymers for gene delivery , 2005, Nature Reviews Drug Discovery.

[192]  Xiaobing Zhang,et al.  Enhanced Targeted Gene Transduction: AAV2 Vectors Conjugated to Multiple Aptamers via Reducible Disulfide Linkages. , 2018, Journal of the American Chemical Society.

[193]  Xiaojuan He,et al.  Progress and Challenges in Developing Aptamer-Functionalized Targeted Drug Delivery Systems , 2015, International journal of molecular sciences.

[194]  L. Huang,et al.  pH-sensitive immunoliposomes mediate target-cell-specific delivery and controlled expression of a foreign gene in mouse. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[195]  D. Schmaljohann.  Thermo- and pH-responsive polymers in drug delivery. , 2006, Advanced drug delivery reviews.

[196]  R. Ransohoff,et al.  Development, maintenance and disruption of the blood-brain barrier , 2013, Nature Medicine.

[197]  Andrew D. Ellington,et al.  Aptamer mediated siRNA delivery , 2006, Nucleic acids research.

[198]  J. Weitz,et al.  Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa , 2017, Scientific Reports.

[199]  M. Wood,et al.  Biological gene delivery vehicles: beyond viral vectors. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[200]  Steven A Carr,et al.  Protein biomarker discovery and validation: the long and uncertain path to clinical utility , 2006, Nature Biotechnology.

[201]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[202]  D. Kong,et al.  Direct Visualization of RNA-DNA Primer Removal from Okazaki Fragments Provides Support for Flap Cleavage and Exonucleolytic Pathways in Eukaryotic Cells* , 2017, The Journal of Biological Chemistry.

[203]  P. Low,et al.  Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. , 2005, Analytical biochemistry.

[204]  Philip S Low,et al.  Ligand-Targeted Drug Delivery. , 2017, Chemical reviews.

[205]  Jeannie T. Lee.  Epigenetic Regulation by Long Noncoding RNAs , 2012, Science.

[206]  E. Uribe-Querol,et al.  Phagocytosis: A Fundamental Process in Immunity , 2017, BioMed research international.

[207]  Jian Wang,et al.  TLR3 ligand Poly IC Attenuates Reactive Astrogliosis and Improves Recovery of Rats after Focal Cerebral Ischemia , 2015, CNS neuroscience & therapeutics.

[208]  Jiancheng Wang,et al.  Brain tumor-targeted therapy by systemic delivery of siRNA with Transferrin receptor-mediated core-shell nanoparticles. , 2016, International journal of pharmaceutics.

[209]  S. Silverman,et al.  Systematic evaluation of the dependence of deoxyribozyme catalysis on random region length. , 2012, ACS combinatorial science.

[210]  D. Richardson,et al.  The role of iron in cell cycle progression and the proliferation of neoplastic cells. , 2002, Biochimica et biophysica acta.

[211]  K. Pärn,et al.  PEG shielded MMP sensitive CPPs for efficient and tumor specific gene delivery in vivo. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[212]  C. F. Bennett,et al.  Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents , 2003, The Journal of Biological Chemistry.

[213]  G. Gellerman,et al.  Targeted drug delivery for cancer therapy: the other side of antibodies , 2012, Journal of Hematology & Oncology.

[214]  J. Rossi,et al.  Methods for assembling B-cell lymphoma specific and internalizing aptamer-siRNA nanoparticles via the sticky bridge. , 2015, Methods in molecular biology.

[215]  J. Kjems,et al.  Folic acid conjugated chitosan for targeted delivery of siRNA to activated macrophages in vitro and in vivo. , 2014, Journal of materials chemistry. B.

[216]  Anthony D. Keefe,et al.  Aptamers as therapeutics , 2010, Nature Reviews Drug Discovery.

[217]  M. Mytilinaiou,et al.  Asialoglycoprotein receptor (ASGPR): a peculiar target of liver-specific autoimmunity , 2012, Autoimmunity Highlights.

[218]  Haibin Xia,et al.  siRNA-mediated gene silencing in vitro and in vivo , 2002, Nature Biotechnology.

[219]  P. Low,et al.  Folate-targeted therapies for cancer. , 2010, Journal of medicinal chemistry.

[220]  Feng Liu,et al.  A highly efficient synthetic vector: nonhydrodynamic delivery of DNA to hepatocyte nuclei in vivo. , 2013, ACS nano.

[221]  Forrest M Kievit,et al.  Chlorotoxin labeled magnetic nanovectors for targeted gene delivery to glioma. , 2010, ACS nano.

[222]  J. Rossi,et al.  Functional In Vivo Delivery of Multiplexed Anti-HIV-1 siRNAs via a Chemically Synthesized Aptamer With a Sticky Bridge , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[223]  J. Rosenecker,et al.  siRNA delivery by magnetofection. , 2008, Current opinion in molecular therapeutics.

[224]  Mark W. Tibbitt,et al.  Scalable manufacturing of biomimetic moldable hydrogels for industrial applications , 2016, Proceedings of the National Academy of Sciences.

[225]  Ashok Kumar,et al.  Thermo-responsive polymers: structure and design of smart materials , 2015 .

[226]  R. Shiekhattar,et al.  TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing , 2005, Nature.

[227]  Robert Langer,et al.  Parallel synthesis and biophysical characterization of a degradable polymer library for gene delivery. , 2003, Journal of the American Chemical Society.

[228]  Hongbo Zeng,et al.  Asialoglycoprotein Receptor-Mediated Gene Delivery to Hepatocytes Using Galactosylated Polymers. , 2015, Biomacromolecules.

[229]  T. Denning,et al.  Fab'-bearing siRNA TNFα-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[230]  Maite Huarte.  The emerging role of lncRNAs in cancer , 2015, Nature Medicine.

[231]  D. He,et al.  Aptamer-Functionalized and Backbone Redox-Responsive Hyperbranched Polymer for Targeted Drug Delivery in Cancer Therapy. , 2016, Biomacromolecules.

[232]  Ke Chen,et al.  Cell-specific aptamers and their conjugation with nanomaterials for targeted drug delivery , 2015, Expert opinion on drug delivery.

[233]  Samir Mitragotri,et al.  Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies , 2014, Nature Reviews Drug Discovery.

[234]  Wei Yang,et al.  Crystal Structures of RNase H Bound to an RNA/DNA Hybrid: Substrate Specificity and Metal-Dependent Catalysis , 2005, Cell.

[235]  K. Jensen-Pergakes,et al.  Evolving phage vectors for cell targeted gene delivery. , 2002, Current pharmaceutical biotechnology.

[236]  J. Lieberman,et al.  Knocking down disease: a progress report on siRNA therapeutics , 2015, Nature Reviews Genetics.

[237]  Anitha Rao,et al.  RNA-Based Gene Therapy for HIV with Lentiviral Vector–Modified CD34+ Cells in Patients Undergoing Transplantation for AIDS-Related Lymphoma , 2010, Science Translational Medicine.

[238]  V. C. Malshe,et al.  Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma , 2017, Drug delivery.

[239]  Khaled Greish,et al.  Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. , 2010, Methods in molecular biology.

[240]  J. Byrd,et al.  Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2. , 2009, Molecular pharmaceutics.

[241]  W. Liu,et al.  The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes. , 2011, Biomaterials.

[242]  J. Rossi,et al.  Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery. , 2011, Journal of visualized experiments : JoVE.

[243]  E. Wagner,et al.  Epidermal growth factor-PEG functionalized PAMAM-pentaethylenehexamine dendron for targeted gene delivery produced by click chemistry. , 2011, Biomacromolecules.

[244]  Jianjun Cheng,et al.  Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles , 2004, Cancer biology & therapy.

[245]  F. Caruso,et al.  Redox-active polymer microcapsules for the delivery of a survivin-specific siRNA in prostate cancer cells. , 2011, ACS nano.

[246]  A. Misra,et al.  Antisense Oligonucleotides and RNA Interference , 2011, Challenges in Delivery of Therapeutic Genomics and Proteomics.

[247]  Michael Blank,et al.  Aptamer Selection Technology and Recent Advances , 2015, Molecular therapy. Nucleic acids.

[248]  P. Swaan,et al.  Endocytic mechanisms for targeted drug delivery. , 2007, Advanced drug delivery reviews.

[249]  Simon C Watkins,et al.  Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. , 2012, Blood.

[250]  V. Torchilin.  Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery , 2014, Nature Reviews Drug Discovery.

[251]  Y. Ohya,et al.  Design of quaternary chitosan conjugate having antennary galactose residues as a gene delivery tool , 1997 .

[252]  H. McMahon,et al.  Mechanisms of endocytosis. , 2009, Annual review of biochemistry.

[253]  Vladimir R Muzykantov,et al.  Drug delivery by red blood cells: vascular carriers designed by mother nature , 2010, Expert opinion on drug delivery.

[254]  Xin-guo Jiang,et al.  A cascade targeting strategy for brain neuroglial cells employing nanoparticles modified with angiopep-2 peptide and EGFP-EGF1 protein. , 2011, Biomaterials.

[255]  V. Weaver,et al.  Tissue Force Programs Cell Fate and Tumor Aggression. , 2017, Cancer discovery.

[256]  R. Jain,et al.  Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. , 2013, Cancer research.

[257]  M. Shoichet,et al.  Click conjugated polymeric immuno-nanoparticles for targeted siRNA and antisense oligonucleotide delivery. , 2013, Biomaterials.

[258]  Shijie Cao,et al.  Angiopep-2 and activatable cell-penetrating peptide dual-functionalized nanoparticles for systemic glioma-targeting delivery. , 2014, Molecular pharmaceutics.

[259]  Michael R Hamblin,et al.  Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems. , 2016, Chemical Society reviews.

[260]  Yingfu Li,et al.  Recognition of anionic porphyrins by DNA aptamers. , 1996, Biochemistry.

[261]  Cao Xie,et al.  Retro-inverso isomer of Angiopep-2: a stable d-peptide ligand inspires brain-targeted drug delivery. , 2014, Molecular pharmaceutics.

[262]  T. Nagai,et al.  Functional folate receptor beta-expressing macrophages in osteoarthritis synovium and their M1/M2 expression profiles , 2012, Scandinavian journal of rheumatology.

[263]  Erkki Ruoslahti,et al.  Targeted quantum dot conjugates for siRNA delivery. , 2007, Bioconjugate chemistry.

[264]  S. Ferretti,et al.  Tumor interstitial fluid pressure as an early-response marker for anticancer therapeutics. , 2009, Neoplasia.

[265]  Hua Yu,et al.  In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses , 2009, Nature Biotechnology.